Document is current

Any future updates will be listed below

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

Crossref DOI link: https://doi.org/10.1186/s13063-023-07546-z

Published Online: 2023-07-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark